F S&P 500
5,046.50 -61.00 (-1.19%) F Dow Jones
38,253.00 -427.00 (-1.10%) F Nasdaq
17,388.25 -276.25 (-1.56%) E-mini Russell 2000 Index Futur
1,985.90 -20.90 (-1.04%) Petróleo
82.93 +0.12 (+0.14%) Oro
2,341.90 +3.50 (+0.15%)
GSK plc (GSK.L)
GSK plc
980 Great West Road
Middlesex
Brentford TW8 9GS
United Kingdom
44 20 8047 5000
https://www.gsk.com
Sector(es): Healthcare
Industria: Drug Manufacturers - General
Empleados a tiempo completo: 70,212
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Ms. Emma Natasha Walmsley | CEO & Director | 5.39M | 53.92M | 1969 |
| Ms. Julie Belita Brown | CFO & Executive Director | 5.14M | N/D | 1962 |
| Ms. Shobie Ramakrishnan | Chief Digital & Technology Officer | N/D | N/D | 1971 |
| Mr. Tony Wood | Chief Scientific Officer and Head of R&D | N/D | N/D | N/D |
| Ms. Sarah Elton-Farr | Head of Investor Relations | N/D | N/D | N/D |
| Mr. James Ford | Senior VP & Group General Counsel of Legal & Compliance | N/D | N/D | N/D |
| Ms. Sally Jackson | Senior Vice President of Global Communications & CEO Office | N/D | N/D | N/D |
| Mr. David Simon Redfern BSc (Hons), CA | President of Corporate Development | N/D | N/D | 1966 |
| Ms. Diana Conrad | Chief People Officer | N/D | N/D | N/D |
| Mr. Philip C. Thomson | President of Global Affairs | N/D | N/D | N/D |
Descripción
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Gestión corporativa
La calificación ISS Governance QuickScore de GSK plc a partir del 1 de abril de 2024 es 9. Las puntuaciones principales son Auditoría: 10; Junta: 7; Derechos del accionista: 1; Compensación: 10.
